Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by jdstoxon Dec 09, 2017 2:06pm
225 Views
Post# 27124028

RE:Is Denali’s BBB technology a competitor

RE:Is Denali’s BBB technology a competitor Denali = transferrin receptor. 'nuff said.

I think Denali is legit and it has been fantastically well promoted. They had a big win with their IPO. Good for them.

But the antibody transport platform on transferrin and not melanotransferrin as ours is.

We lost a lot of years and could have been so far ahead of these guys. There may even be an argument that had we progressed as we should have, some competing technologies may not exist at all today.

But in the end, it will be the best technology that stands the tallest. Our knowledge of xB3 indicates that it beats Denali's and Genentech's Brain Shuttle, hands down. How close Denali's platform is to Brain Shuttle is unclear to me, but the company was founded and is populated by ex-Genentech people who worked on Brain Shuttle. Yes, they can get some stuff into the brain, but far less per given dose than we can. They probably would have to use much higher doses to achieve the delivered quantities to the brain as we can. For Denali that would mean that their treatments would be more costly and more likely to be toxic than equivalent delivered doses with xB3.

Denali's small molecule programs may not be based on receptor mediated transcytosis but as I've written before, when a molecule has to be designed to both cross the BBB and to be efficacious, then it's very difficult, and often impossible, to achieve optimal performance with either function. The beauty of a universal or near-universal carrier like we hope xB3 turns out to be is that it can cross the BBB no matter what the payload is and the payload can be designed for the single purpose of treating the disease - no conflicting purposes between xB3 and the payload.

My opinion, and that of others, has been that Brain Shuttle, whether at Genentech or Denali, is not capable of the performance that xB3 can achieve.

Denali is pretty secretive. As we make some news and come to the attention of the pharmaceutical industry, it's going to be interesting to see how they respond to little old Bioasis.

jdstox
Bullboard Posts